Symbols

CADL

Candel Therapeutics·NASDAQ

--(--)

CADL Profile

Candel Therapeutics, Inc.

A late clinical stage biopharmaceutical company that develops novel oncolytic viral immunotherapies

Industry

Biological Technology

Established Date

Listing Date

07/27/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.candeltx.com

Security Type

Common stock

Office address

117 Kendrick St, Suite 450, Needham, MA 02494

Business

Introduction

Candel Therapeutics, Inc., was incorporated in Delaware in June 2003. The company is a clinical-stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies designed to induce a systemic anti-tumor immune response. Its lead drug candidate, aglatimagene besadenovec, is an adenovirus-based therapy that is being studied in a variety of solid tumor indications.